Early Clinical Pursuing clinical studies and FDA 510(k) path for a point-of-care concussion diagnostic device (DXPH-901) presents a direct sales opportunity to healthcare providers, urgent care centers, and sports medicine clinics seeking rapid, biomarker-based mTBI testing.

Therapeutic Portfolio Companion therapeutic TXPH-301 aims to modulate the inflammatory cascade in neurological trauma, opening potential collaboration or procurement channels with pharmaceutical partners, research hospitals, and clinical trial networks focusing on neuroinflammation and TBI.

Trauma Market Target institutions include neurology, emergency departments, sports medicine, and military or veteran health programs that require objective concussion assessment tools and follow-up monitoring, enabling multi-phase deployments from baseline to post-injury data collection.

Clinical Evidence Readiness Preclinical data supporting the diagnostic approach and ready-to-start clinical studies indicate receptiveness to early adopter sites, contract research organizations, and academic medical centers for pilot programs and regulatory-led demonstrations.

Small Team Advantage As a small biotechnology outfit with a focused mandate, pHLOGISTIX can leverage strategic partnerships with larger CROs, diagnostics companies, and device manufacturers to scale validation, manufacturing, and go-to-market activities efficiently.